St John’s wort greatly decreases the plasma concentrations of oral S‐ketamine
- 2 June 2011
- journal article
- research article
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 26 (6) , 743-750
Abstract
Ketamine is an intravenous anaesthetic and analgesic agent but it can also be used orally as an adjuvant in the treatment of chronic pain. This study investigated the effect of the herbal antidepressant St John’s wort, an inducer of cytochrome P450 3A4 (CYP3A4), on the pharmacokinetics and pharmacodynamics of oral S‐ketamine. In a randomized cross‐over study with two phases, 12 healthy subjects were pretreated with oral St John’s wort or placebo for 14 days. On day 14, they were given an oral dose of 0.3 mg/kg of S‐ketamine. Plasma concentrations of ketamine and norketamine were measured for 24 h and pharmacodynamic variables for 12 h. St John’s wort decreased the mean area under the plasma concentration–time curve (AUC0–∞) of ketamine by 58% (P < 0.001) and decreased the peak plasma concentration (Cmax) of ketamine by 66% (P < 0.001) when compared with placebo. MeanCmaxof norketamine (the major metabolite of ketamine) was decreased by 23% (P = 0.002) and mean AUC0–∞of norketamine by 18% (P < 0.001) by St John’s wort. There was a statistically significant linear correlation between the self‐reported drug effect andCmaxof ketamine (r = 0.55;P < 0.01). St John’s wort greatly decreased the exposure to oral S‐ketamine in healthy volunteers. Although this decrease was not associated with significant changes in the analgesic or behavioural effects of ketamine in the present study, usual doses of S‐ketamine may become ineffective if used concomitantly with St John’s wort.Keywords
This publication has 58 references indexed in Scilit:
- St John's wort greatly reduces the concentrations of oral oxycodoneEuropean journal of pain, 2010
- Use of Alternative Medicines by Patients with OA that Adversely Interact with Commonly Prescribed MedicationsClinical Orthopaedics and Related Research, 2009
- The recovery time‐course of CYP3A after induction by St John's wort administrationBritish Journal of Clinical Pharmacology, 2008
- Chronic Administration of Ketamine for AnalgesiaJournal of Pain & Palliative Care Pharmacotherapy, 2007
- The effect of St John’s wort extracts on CYP3A: a systematic review of prospective clinical trialsBritish Journal of Clinical Pharmacology, 2006
- Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse historyJournal of Pain and Symptom Management, 2004
- Contribution of CYP3A4, CYP2B6, and CYP2C9 Isoforms to N-Demethylation of Ketamine in Human Liver MicrosomesDrug Metabolism and Disposition, 2002
- St John's Wort increases expression of P‐glycoprotein: Implications for drug interactionsBritish Journal of Clinical Pharmacology, 2002
- Ketamine as an AnalgesicJournal of Pain & Palliative Care Pharmacotherapy, 2002
- Update on the Neurophysiology of Pain Transmission and ModulationJournal of Pain and Symptom Management, 2000